Novavax (NVAX) Stock Forecast, Price & News

Novavax (NASDAQ:NVAX) Frequently Asked Questions

Is Novavax a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Novavax stock.
View analyst ratings for Novavax or view top-rated stocks.

When is Novavax's next earnings date?

Novavax is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Novavax.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) released its earnings results on Monday, May, 9th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.33 by $0.77. The biopharmaceutical company earned $703.97 million during the quarter, compared to analyst estimates of $845.20 million. Novavax had a negative net margin of 93.91% and a negative trailing twelve-month return on equity of 572.54%. The business's revenue for the quarter was up 57.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($3.05) earnings per share.
View Novavax's earnings history.

When did Novavax's stock split? How did Novavax's stock split work?

Shares of Novavax reverse split on the morning of Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

What guidance has Novavax issued on next quarter's earnings?

Novavax issued an update on its FY 2022 earnings guidance on Monday, May, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.00 billion-$5.00 billion, compared to the consensus revenue estimate of $4.49 billion.

What price target have analysts set for NVAX?

8 brokers have issued 12 month target prices for Novavax's stock. Their forecasts range from $35.00 to $209.00. On average, they expect Novavax's share price to reach $164.86 in the next year. This suggests a possible upside of 198.2% from the stock's current price.
View analysts' price targets for Novavax or view top-rated stocks among Wall Street analysts.

Who are Novavax's key executives?

Novavax's management team includes the following people:

• Mr. Stanley Charles Erck, Pres, CEO & Director (Age 74, Pay $1.26M)
• Mr. John A. Herrmann III, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 56, Pay $655.95k) (LinkedIn Profile)
• Mr. John Joseph Trizzino B.S., M.B.A., Exec. VP and Chief Bus. & Commercial Officer (Age 62, Pay $676.83k)
• Dr. Gregory M. Glenn, Pres of R&D (Age 68, Pay $857.42k) (LinkedIn Profile)
• Mr. James Patrick Kelly C.F.A., Exec. VP, CFO & Treasurer (Age 56)
• Mr. Richard P. Crowley, Exec. VP & COO (Age 65)
• Dr. Gale E. Smith, Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist (Age 72)
• Mr. Biegie Lee, Sr. VP & Chief Information Officer
• Ms. Silvia Taylor M.B.A., MBA, Sr. VP of Global Corp. Affairs & Investor Relations
• Mr. Troy Morgan Esq., Sr. VP & Chief Compliance Officer (Age 51)

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax CEO Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among Novavax's employees.

Who are some of Novavax's key competitors?

Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Exact Sciences (EXAS), Repligen (RGEN), Neurocrine Biosciences (NBIX), Halozyme Therapeutics (HALO) and Exelixis (EXEL).
View all of NVAX's competitors.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.92%), State Street Corp (3.19%), Citigroup Inc. (0.00%), Jane Street Group LLC (0.00%), Coatue Management LLC (1.13%) and JPMorgan Chase & Co. (0.00%). Company insiders that own Novavax stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends for Novavax.

Which institutional investors are selling Novavax stock?

NVAX stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Capital World Investors, Jane Street Group LLC, PEAK6 Investments LLC, Graham Capital Management L.P., Simplex Trading LLC, First Trust Advisors LP, and Group One Trading L.P.. Company insiders that have sold Novavax company stock in the last year include David M Mott, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, and Stanley C Erck.
View insider buying and selling activity for Novavax or view top insider-selling stocks.

Which institutional investors are buying Novavax stock?

NVAX stock was bought by a variety of institutional investors in the last quarter, including Coatue Management LLC, State Street Corp, Citigroup Inc., Goldman Sachs Group Inc., Capital Fund Management S.A., Qube Research & Technologies Ltd, International Biotechnology Trust PLC, and JPMorgan Chase & Co.. Company insiders that have bought Novavax stock in the last two years include James F Young, and Rachel K King.
View insider buying and selling activity for Novavax or or view top insider-buying stocks.

How do I buy shares of Novavax?

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $55.29.

How much money does Novavax make?

Novavax has a market capitalization of $4.32 billion and generates $1.15 billion in revenue each year. The biopharmaceutical company earns $-1.74 billion in net income (profit) each year or ($17.680010) on an earnings per share basis.

How many employees does Novavax have?

Novavax employs 1,541 workers across the globe.

When was Novavax founded?

Novavax was founded in 1987.

What is Novavax's official website?

The official website for Novavax is www.novavax.com.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at [email protected], or via fax at 240-268-2100.